Patients with active collagenous colitis were randomly assigned to groups given pH-modified release oral budesonide capsules ( @ mg budesonide once daily , Budenofalk , n = @ ) , mesalamine granules ( @ g mesalamine once daily , Salofalk , n = @ ) , or placebo for @ weeks ( n = @ ) in a double-blind , double-dummy fashion .